[Recurrent signet-ring cell gastric carcinoma evidenced by FDG-PET].

Objective: To present the case report of a patient with undifferentiated and diffuse signet-ring cell gastric carcinoma in which FDG-PET evidenced recurrent disease.

Materials And Methods: The patient was diagnosed of a stage III gastric carcinoma in 1994 and was treated with a subtotal gastrectomy. In February 2003, recurrent disease was detected in mediastinal and left supraclavicular lymph nodes.

[Meta-analysis of the diagnostic efficacy of FDG-PET in patients with suspected ovarian cancer recurrence].

Aim: The aim of this paper was to perform a meta-analysis of the literature to evaluate the accuracy of FDG-PET in recurrence detection in patients with ovarian cancer.

Methods: The search strategy consisted in identifying papers published between November 1972 and October 2003 indexed in MEDLINE and CANCERLITE. Inclusion criteria were publications that evaluated recurrence with FDG-PET in patients with ovarian carcinoma.

[Impact of positron emission tomography with FDG-PET in treatment of patients with suspected recurrent ovarian cancer].

Aim: Recurrent ovarian cancer is a major problem and an accurate diagnosis can often change patients' management. This study aimed to assess the impact on management of FDG-PET in recurrent ovarian cancer.

Material And Methods: Forty-three patients in whom FDG-PET scan was performed due to suspected recurrent ovarian cancer were included.

[The value of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG PET) in diagnosis of neoplastic diseases].

Positron emission tomography (PET) has the ability to detect cancer based on molecular and biochemical processes within the tumor tissues. The most widely used radiotracer in oncology at this time is the glucose analogue 18F-fluoro-2-deoxy-D-glucose (18F-FDG). Like glucose, 18F-FDG is transported into cells by a glucose transporter protein and rapidly converted into 18F-FDG-6-phosphate.

[Positron emission tomography using 18-FDG-PET in radiologically indeterminate pulmonary lesions].

Objective: Fluorine-18 deoxyglucose Positron Emission Tomography (FDG-PET) is a non-invasive technique that offers the possibility to define if the radiologically indetermined pulmonary lesions are benign or malignant with high positive and negative predictive values. Considering the indexed literature we can observe that there are few original studies performed with the diagnostic possibilities of our means. For this reason, our main objective is to evaluate the diagnostic accuracy of positron emission tomography in sixty-seven radiologically indetermined pulmonary nodular lesions.